-- 首席醫療官彭璐於2026年5月1日出售了Pharvaris（PHVS）的14,166股股票，套現427,419美元。根據向美國證券交易委員會（SEC）提交的4號表格文件，彭璐目前控制該公司共66,083股普通股，其中66,083股為直接持有。 SEC文件連結： https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xml
Price: $29.94, Change: $-0.08, Percent Change: -0.27%
Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml